Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -0.12%91 Return-on-Tangible-Equity is 10.13% as of Mar. 2026, which is 23% above its 10-year median of 8.25. GuruFocus rates DHA:ACMELAB with a GF Score™ of 91/100 and a GF Value™ of BDT125.72 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 901 Drug Manufacturers companies, ACME Laboratories ranks worse than 51.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ACME Laboratories's annualized net income for the quarter that ended in Mar. 2026 was BDT2,792 Mil. ACME Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was BDT27,561 Mil. Therefore, ACME Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.13%.
The historical rank and industry rank for ACME Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
DHA:ACMELAB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.73 Med: 8.25 Max: 10.24
Current: 7.34
During the past 9 years, ACME Laboratories's highest Return-on-Tangible-Equity was 10.24%. The lowest was 6.73%. And the median was 8.25%.
DHA:ACMELAB's Return-on-Tangible-Equity is ranked worse than 51.39% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs DHA:ACMELAB: 7.34
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ACME Laboratories Return-on-Tangible-Equity Related Terms
ACME Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.13% mean?
ACME Laboratories (DHA:ACMELAB) has a Return-on-Tangible-Equity of 10.13% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ACME Laboratories and its competitors. This is 23% above median its historical median of 8.25. Over the past decade, ACME Laboratories' Return-on-Tangible-Equity has ranged from 6.73 to 10.24. According to the industry distribution chart, ACME Laboratories ranks #463 out of 901 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is ACME Laboratories' Return-on-Tangible-Equity too high?
ACME Laboratories' current Return-on-Tangible-Equity of 10.13% is 23% above median its 10-year median of 8.25. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 10.24. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. ACME Laboratories' value of 10.13% is 28.2% above this industry median. Based on the distribution chart, ACME Laboratories ranks #463 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 91/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #463 out of 901 companies for Return-on-Tangible-Equity. This places ACME Laboratories in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. ACME Laboratories' value of 10.13% is 28.2% above this benchmark. Historically, ACME Laboratories' own Return-on-Tangible-Equity has ranged from 6.73 to 10.24 over the past decade. While the company's 10-year median is 8.25 vs. the industry median of 7.90, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Return-on-Tangible-Equity of 10.13% is 28.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Return-on-Tangible-Equity is 10.13%, which is 23% above median its own 10-year median of 8.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.72, compared to a current price of BDT86.80 — trading 31% below its estimated fair value. The current Return-on-Tangible-Equity is 10.13%, which is 23% above median its 10-year median of 8.25 and 28.2% above the Drug Manufacturers industry median of 7.90. ACME Laboratories' overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Return-on-Tangible-Equity is 10.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT86.80 is trading 31% below its estimated GF Value™ of BDT125.72.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Return-on-Tangible-Equity: 10.13% (23% above median its 10-year median of 8.25)
GF Value™: BDT125.72 vs. price of BDT86.80 (31% below fair value)
Industry Position: 28.2% above the Drug Manufacturers median (#463 of 901)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
91GF Score
Get the complete analysis for DHA:ACMELAB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
